The antiserum was produced against synthesized peptide derived from human mTOR around the phosphorylation site of Ser2481. AA range:2447-2496

Phospho-mTOR (S2481) Polyclonal Antibody detects endogenous levels of mTOR protein only when phosphorylated at S2481.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):IHsFI

MTOR

Serine/threonine-protein kinase mTOR

MTOR ;
FRAP ;
FRAP1 ;
FRAP2 ;
RAFT1 ;
RAPT1 ;
Serine/threonine-protein kinase mTOR ;
FK506-binding protein 12-rapamycin complex-associated protein 1 ;
FKBP12-rapamycin complex-associated protein ;
Mammalian target of rapamycin ;
mTOR ;
Mechanistic tar

The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. The ANGPTL7 gene is located in an intron of this gene. [provided by RefSeq, Sep 2008],

Function:Acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. Part of the TORC2 complex which plays a critical role in AKT1 Ser-473 phosphorylation, and may modulate the phosphorylation of PKCA and regulate actin cytoskeleton organization.,similarity:Belongs to the PI3/PI4-kinase family.,similarity:Contains 1 FAT domain.,similarity:Contains 1 FATC domain.,similarity:Contains 1 PI3K/PI4K domain.,similarity:Contains 7 HEAT repeats.,subunit:Interacts with the FKBP12-rapamycin complex. Binds UBQLN1. Forms part of the mammalian target of rapamycin 2 complex (TORC2) comprised of FRAP1, GBL, PRR5, RICTOR and SIN. TORC2 does not bind to and is not sensitive to FKBP12-rapamycin. Binds directly to PRR5 and RICTOR within the TORC2 complex.,tissue specificity:Expressed in numerous tissues, with highest levels in testis.,

Endoplasmic reticulum membrane ; Peripheral membrane protein ; Cytoplasmic side . Golgi apparatus membrane ; Peripheral membrane protein ; Cytoplasmic side . Mitochondrion outer membrane ; Peripheral membrane protein ; Cytoplasmic side . Lysosome . Cytoplasm . Nucleus, PML body . Microsome membrane . Lysosome membrane . Cytoplasmic vesicle, phagosome . Shuttles between cytoplasm and nucleus. Accumulates in the nucleus in response to hypoxia (By similarity). Targeting to lysosomes depends on amino acid availability and RRAGA and RRAGB (PubMed:18497260, PubMed:20381137). Lysosome targeting also depends on interaction with MEAK7. Translocates to the lysosome membrane in the presence of TM4SF5 (PubMed:30956113). .

>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>ErbB signaling pathway ;
>>HIF-1 signaling pathway ;
>>Phospholipase D signaling pathway ;
>>Autophagy - other ;
>>Autophagy - animal ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>AMPK signaling pathway ;
>>Longevity regulating pathway ;
>>Longevity regulating pathway - multiple species ;
>>Cellular senescence ;
>>Apelin signaling pathway ;
>>Neutrophil extracellular trap formation ;
>>JAK-STAT signaling pathway ;
>>Th17 cell differentiation ;
>>Thermogenesis ;
>>Insulin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Adipocytokine signaling pathway ;
>>Type II diabetes mellitus ;
>>Insulin resistance ;
>>Growth hormone synthesis, secretion and action ;
>>Alzheimer disease ;
>>Amyotrophic lateral sclerosis ;
>>Huntington disease ;
>>Spinocerebellar ataxia ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Shigellosis ;
>>Human cytomegalovirus infection ;
>>Human papillomavirus infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Human immunodeficiency virus 1 infection ;
>>Pathways in cancer ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - receptor activation ;
>>Colorectal cancer ;
>>Pancreatic cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Acute myeloid leukemia ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer ;
>>Central carbon metabolism in cancer ;
>>Choline metabolism in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Diabetic cardiomyopathy